Literature DB >> 2566079

Cyclophosphamide in severe polymyositis.

S Bombardieri, G R Hughes, R Neri, P Del Bravo, L Del Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2566079     DOI： 10.1016/s0140-6736(89)92416-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors:  I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

Review 2.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis.

Authors:  H J Haga; D D'Cruz; R Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

4.  Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study.

Authors:  Salvatore D'Angelo; Giovanna Cuomo; Carmen Paone; Emiliana Colutta; Giovanni La Montagna; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2003-10-23       Impact factor: 2.980

Review 5.  Current Treatment for Myositis.

Authors:  Simone Barsotti; Ingrid E Lundberg
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.